Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Risk Factors for Paclitaxel-Induced Peripheral Neuropathy in Patients With Breast Cancer Publisher Pubmed



Ghoreishi Z1 ; Keshavarz S2 ; Asghari Jafarabadi M3 ; Fathifar Z4 ; Goodman KA5 ; Esfahani A6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran
  2. 2. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  4. 4. School of Health, Tabriz University of Medical Sciences, Tabriz, Iran
  5. 5. Department of Radiation Oncology, School of Medicine, University of Colorado, Aurora, CO, United States
  6. 6. Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Shahid Ghazi Hospital, Tabriz, Iran

Source: BMC Cancer Published:2018


Abstract

Background: Paclitaxel induced peripheral neuropathy (PIPN) is a major debilitating side effect of paclitaxel in patients with breast cancer with no fully known mechanisms. The aim of the study was to find out the possible risk factors for PIPN. Methods: Eligible patients with node positive breast cancer undergoing chemotherapy with paclitaxel were assessed. They belonged to an initial randomized controlled trial in which the effectiveness of omega-3 fatty acids in preventing and reducing severity of PIPN was evaluated (protocol ID: NCT01049295). Reduced total neuropathy score (r-TNS) was used for measuring PIPN. All analyses were performed adjusting for intervention effect. The association between age, BMI, BSA, pathological grade, molecular biomarkers and PIPN was evaluated. Results: Fifty-seven patients with breast cancer were investigated. Age was significantly associated with risk of PIPN (RR:1.50, P value =.024). Body mass index and BSA had significant association with severity of PIPN (B:1.28, P =.025; and B: 3.88, P =.010 respectively). Also, BSA showed a significant association with the risk of PIPN (RR: 2.28, P =.035; B: 3.88, P =.035). Incidence and severity of PIPN were much more pronounced in progesterone receptor positive (PR+) patients (RR:1.88, P =.015 and B:1.54, P =.012). Multivariate analysis showed that age and the status of PR+ were independent risk factor for incidence and the status of PR+ was the only independent risk factor for severity of PIPN. Conclusion: Age, BSA and the status of PR+, should be considered as the risk factors for PIPN before commencement of chemotherapy with paclitaxel in patients with breast cancer. Older patients, those with greater BSA and PR+ patients may need closer follow up and more medical attention due to greater incidence and severity of PIPN. © 2018 The Author(s).
Related Docs
1. Lithium and Preventing Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients: A Placebo-Controlled Randomized Clinical Trial, Trials (2021)